Aims and Scope of Expert Review of Anticancer Therapy
Expert Review of Anticancer Therapy is a monthly peer-reviewed medical journal covering all clinical aspects of cancer therapy. It was established in 2001 and is published by Taylor & Francis under the academic publishing division of Informa. The current Editor-in-Chief is Gertjan J L Kaspers who is Head of Pediatric Oncology at VU University Medical Center Amsterdam. According to Journal Citation Reports, the journal has a 2019 impact factor of 3.573. Less
Key Metrics
CiteScore 

6.7
Eigenfactor 

0.001 - 0.005
H-Index 

79
Impact Factor 

< 5
SJR 

Q2Oncology

SNIP 

1.08
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Review of Anticancer Therapy
Expert Review of Anticancer Therapy Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Review of Anticancer Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Review of Anticancer Therapy
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state of the art
- 3 Oct 2026
- Expert Review of Anticancer Therapy
Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy
- 3 Oct 2026
- Expert Review of Anticancer Therapy
Optic glioma in children: clinical presentation, diagnosis, and management
- 3 Oct 2026
- Expert Review of Anticancer Therapy
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis
- 2 Sep 2026
- Expert Review of Anticancer Therapy
Complications following small-molecule inhibitors for non-small cell lung cancer
- 2 Sep 2026
- Expert Review of Anticancer Therapy
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer
- 2 Sep 2026
- Expert Review of Anticancer Therapy
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state of the art
- 3 Oct 2026
- Expert Review of Anticancer Therapy
Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy
- 3 Oct 2026
- Expert Review of Anticancer Therapy
Optic glioma in children: clinical presentation, diagnosis, and management
- 3 Oct 2026
- Expert Review of Anticancer Therapy
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis
- 2 Sep 2026
- Expert Review of Anticancer Therapy
Complications following small-molecule inhibitors for non-small cell lung cancer
- 2 Sep 2026
- Expert Review of Anticancer Therapy
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer
- 2 Sep 2026
- Expert Review of Anticancer Therapy